Literature DB >> 23889318

Emerging therapeutic aspects in oncology.

David J Macewan.   

Abstract

UNLABELLED: Cancer remains a peculiarly stubborn disease to treat. Some forms of cancer have seen tremendous advances in the effectiveness of their treatments, whereas other forms have remained resistant to pharmacological control. This lack of hope for success is in part due to the types of drugs that are used in the clinic, and the targeted biological system being based purely on cellular growth rates. However, recent drugs designed to affect specific signalling pathways or proteins have been showing much success. Thanks to the ingenuity of pharmacologists in understanding and targeting these processes, there have been real improvements in treatment. Here we are presented with some of the research into such critical systems that have to be understood, so that they can be conquered. We will also look at the challenges facing cancer pharmacologists and what the field may present to us all in the future. LINKED ARTICLES: This article is part of a themed section on Emerging Therapeutic Aspects in Oncology. To view the other articles in this section visit http://dx.doi.org/10.1111/bph.2013.169.issue-8.
© 2013 The British Pharmacological Society.

Entities:  

Keywords:  TKI; biologics; chemotherapy; drug resistance; tumor

Mesh:

Substances:

Year:  2013        PMID: 23889318      PMCID: PMC3753827          DOI: 10.1111/bph.12304

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  9 in total

Review 1.  TNF ligands and receptors--a matter of life and death.

Authors:  David J MacEwan
Journal:  Br J Pharmacol       Date:  2002-02       Impact factor: 8.739

2.  The Late William Blair-Bell, M.D., F.R.C.S.

Authors: 
Journal:  Can Med Assoc J       Date:  1936-06       Impact factor: 8.262

Review 3.  To breathe or not to breathe: the haematopoietic stem/progenitor cells dilemma.

Authors:  C Piccoli; F Agriesti; R Scrima; F Falzetti; M Di Ianni; N Capitanio
Journal:  Br J Pharmacol       Date:  2013-08       Impact factor: 8.739

Review 4.  Targeting survival pathways in chronic myeloid leukaemia stem cells.

Authors:  A Sinclair; A L Latif; T L Holyoake
Journal:  Br J Pharmacol       Date:  2013-08       Impact factor: 8.739

Review 5.  Curcumin: an orally bioavailable blocker of TNF and other pro-inflammatory biomarkers.

Authors:  Bharat B Aggarwal; Subash C Gupta; Bokyung Sung
Journal:  Br J Pharmacol       Date:  2013-08       Impact factor: 8.739

Review 6.  Inhibiting the DNA damage response as a therapeutic manoeuvre in cancer.

Authors:  N J Curtin
Journal:  Br J Pharmacol       Date:  2013-08       Impact factor: 8.739

Review 7.  Death receptors as targets in cancer.

Authors:  O Micheau; S Shirley; F Dufour
Journal:  Br J Pharmacol       Date:  2013-08       Impact factor: 8.739

Review 8.  That which does not kill me makes me stronger; combining ERK1/2 pathway inhibitors and BH3 mimetics to kill tumour cells and prevent acquired resistance.

Authors:  Matthew J Sale; Simon J Cook
Journal:  Br J Pharmacol       Date:  2013-08       Impact factor: 8.739

9.  Common and overlapping oncogenic pathways contribute to the evolution of acute myeloid leukemias.

Authors:  Brynn T Kvinlaug; Wai-In Chan; Lars Bullinger; Mukundhan Ramaswami; Christopher Sears; Donna Foster; Stanley E Lazic; Rachel Okabe; Axel Benner; Benjamin H Lee; Inusha De Silva; Peter J M Valk; Ruud Delwel; Scott A Armstrong; Hartmut Döhner; D Gary Gilliland; Brian J P Huntly
Journal:  Cancer Res       Date:  2011-04-19       Impact factor: 12.701

  9 in total
  1 in total

1.  Epigenetics and pharmacology.

Authors:  Barbara Stefanska; David J MacEwan
Journal:  Br J Pharmacol       Date:  2015-06       Impact factor: 8.739

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.